Oral contraceptives and risk of liver cancer
Menée à l'aide de données de l'étude "Million Women Study (MWS)" et de la "UK Biobank" ainsi qu'à partir d'une revue systématique de la littérature publiée jusqu'en juin 2024, cette méta-analyse évalue l'association entre une utilisation de contraceptifs oraux et le risque de cancer du foie
In this issue of The Lancet Oncology, Cody Z Watling and colleagues1 investigate the relationship between oral contraceptives and liver cancer. Today there are more than 150 million current users of oral contraceptives worldwide, and an even higher number of people will have used this method of contraception in the years since it became available.2 Despite such widespread use, developing the evidence base regarding combined oral contraceptives and liver cancer has been challenging, partly due to the relatively low incidence of liver cancer in women, especially those of reproductive age. Watling and colleagues overcome the difficulty of investigating a rare outcome in their analyses of two of the UK's largest prospective cohorts of women, the Million Women Study (MWS)3 and UK Biobank,4 with a combined sample size of more than 1·5 million participants, 2956 of whom have liver cancer.
The Lancet Oncology , commentaire, 2025